Eagle Pharmaceuticals Long Term Debt

Eagle Pharmaceuticals (EGRX) currently reports a long-term debt of $62M as of June 2023. That compares with $28M in the prior-year period — up 120.9% year over year. Use the charts on this page to explore Eagle Pharmaceuticals's long-term debt history and peer comparisons.

Eagle Pharmaceuticals's long-term debt increased from $28M to $62M — a 120.9% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eagle Pharmaceuticals reported $62M in long-term debt as of June 2023. That compares with $28M in the prior-year period — up 120.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $62M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eagle Pharmaceuticals, and consider following EGRX for alerts when major investors trade the stock.

Eagle Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $62M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EGRX with unrelated industries.